Vera Therapeutics, Inc. (NASDAQ:VERA)
| Market Cap | 2.09B-3.8% |
| Revenue (ttm) | 0 |
| Net Income | -401.89M-84.1% |
| EPS | -5.86-58.0% |
| Shares Out | 71.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 262,729.009 |
| Open | 30.00 |
| Previous Close | 30.25 |
| Day's Range | 29.04 - 30.25 |
| 52-Week Range | 23.05 - 56.05 |
| Beta | 0.95 |
| Analysts | Buy |
| Price Target | 86.75(+198.17%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About VERA
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$VERA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in VERA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VERA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VERA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
VERA Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Payroll and related | $48.54M | 76.33% |
| Commercial planning | $15.06M | 23.67% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New VERA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VERA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VERA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $66.11M |
| XBIState Street SPDR S&P Biotech ETF | $56.53M |
| IWMiShares Russell 2000 ETF | $50.77M |
| VXFVanguard Extended Market ETF | $26.15M |
| IWOiShares Russell 2000 Growth ETF | $18.08M |
| IBBiShares Biotechnology ETF | $13.38M |
Estimated from each fund’s disclosed top holdings × AUM
VERA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VERA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score